BTSG Stock Analysis: BrightSpring Health | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 12.127m USD | 12M Return: 104.9% | US10950A1060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 121M
Qual. Beats: 3
Rev. Trend: 99.7%
Qual. Beats: 6
Warnings
No concerns identified
Tailwinds
Seasonality 2.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BrightSpring Health Services, Inc. (NASDAQ: BTSG) is a U.S.-based home and community-based healthcare services platform operating through two reportable segments: Pharmacy Solutions and Provider Services. The company delivers clinical and supportive care in home and community settings to Medicare, Medicaid, and commercially insured populations, operating within the broader Health Care Services sub-industry where demographic aging and a policy shift toward home- and community-based care have been key demand drivers.
Service offerings span infused, injectable, and oral medication therapies through its pharmacy segment, alongside a provider segment that delivers skilled clinical home health care, rehabilitation services (physical, speech, and occupational therapy), and applied behavioral analysis. This diversified mix positions the company across both pharmaceutical and clinical service lines within the home care value chain.
The company was founded in 1974 and is headquartered in Louisville, Kentucky. It was formerly known as Phoenix Parent Holdings Inc. before adopting its current name in May 2021, and completed its initial public offering on January 26, 2024.
- Home health segment margins expand under Medicare value-based care
- Pharmacy Solutions revenue grows on specialty infusion drug demand
- Medicaid waiver renewals sustain Provider Services reimbursement rates
| Net Income: 294.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.51 > 1.0 |
| NWC/Revenue: 6.36% < 20% (prev 9.53%; Δ -3.17% < -1%) |
| CFO/TA 0.08 > 3% & CFO 506.4m > Net Income 294.0m |
| Net Debt (2.03b) to EBITDA (638.9m): 3.18 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (220.3m) vs 12m ago 1.82% < -2% |
| Gross Margin: 12.38% > 18% (prev 12.88%; Δ -0.49% > 0.5%) |
| Asset Turnover: 240.9% > 50% (prev 201.7%; Δ 39.29% > 0%) |
| Interest Coverage Ratio: 3.14 > 6 (EBIT TTM 478.1m / Interest Expense TTM 152.3m) |
| A: 0.15 (Total Current Assets 2.47b - Total Current Liabilities 1.56b) / Total Assets 5.99b |
| B: 0.01 (Retained Earnings 38.4m / Total Assets 5.99b) |
| C: 0.08 (EBIT TTM 478.1m / Avg Total Assets 5.96b) |
| D: 0.52 (Book Value of Equity 2.05b / Total Liabilities 3.93b) |
| Altman-Z'' = 2.11 = BBB |
| DSRI: 1.02 (Receivables 1.31b/1.07b, Revenue 14.4b/12.0b) |
| GMI: 1.04 (GM 12.88% / 12.38%) |
| AQI: 1.05 (AQ_t 0.52 / AQ_t-1 0.50) |
| SGI: 1.20 (Revenue 14.4b / 12.0b) |
| TATA: -0.04 (NI 294.0m - CFO 506.4m) / TA 5.99b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of October 21, 2026, the stock is trading at USD 62.42 with a total of 1,476,603 shares traded. Over the past week, the price has changed by -0.37%, over one month by +11.74%, over three months by -11.46% and over the past year by +104.86%.
Current recommended Stop Loss: 59.80 (which is 4.2% or 1.3 ATR below the current price).
BrightSpring Health has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy BTSG.
- StrongBuy: 15
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 78.9 | 26.5% |
P/E Trailing = 54.2389
P/E Forward = 22.1729
P/S = 0.8438
P/B = 5.3911
Revenue TTM = 14.4b USD
EBIT TTM = 478.1m USD
EBITDA TTM = 638.9m USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 93.0m USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 196.9m
Net Debt = 2.03b USD (calculated: Debt 2.58b - CCE 550.4m)
Enterprise Value = 14.2b USD (12.1b + Debt 2.58b - CCE 550.4m)
Interest Coverage Ratio = 3.14 (Ebit TTM 478.1m / Interest Expense TTM 152.3m)
EV/FCF = 35.20x (Enterprise Value 14.2b / FCF TTM 402.4m)
FCF Yield = 2.84% (FCF TTM 402.4m / Enterprise Value 14.2b)
FCF Margin = 2.80% (FCF TTM 402.4m / Revenue TTM 14.4b)
Net Margin = 2.05% (Net Income TTM 294.0m / Revenue TTM 14.4b)
Gross Margin = 12.38% ((Revenue TTM 14.4b - Cost of Revenue TTM 12.6b) / Revenue TTM)
Gross Margin QoQ = 12.72% (prev 13.34%)
Tobins Q-Ratio = 2.37 (Enterprise Value 14.2b / Total Assets 5.99b)
Interest Expense / Debt = 5.89% (Interest Expense 152.3m / Debt 2.58b)
Taxrate = 16.11% (47.6m / 295.5m)
NOPAT = 401.1m (EBIT 478.1m * (1 - 16.11%))
Current Ratio = 1.59 (Total Current Assets 2.47b / Total Current Liabilities 1.56b)
Debt / Equity = 1.26 (Debt 2.58b / totalStockholderEquity, last quarter 2.05b)
Debt / EBITDA = 3.18 (Net Debt 2.03b / EBITDA 638.9m)
Debt / FCF = 5.06 (Net Debt 2.03b / FCF TTM 402.4m)
Total Stockholder Equity = 1.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.93% (Net Income 294.0m / Total Assets 5.99b)
RoE = 15.23% (Net Income TTM 294.0m / Total Stockholder Equity 1.93b)
RoCE = 11.72% (EBIT 478.1m / Capital Employed (Equity 1.93b + L.T.Debt 2.15b))
RoIC = 10.10% (NOPAT 401.1m / Invested Capital 3.97b)
WACC = 8.73% (E(12.1b)/V(14.7b) * Re(9.54%) + D(2.58b)/V(14.7b) * Rd(5.89%) * (1-Tc(0.16)))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.30 | Cagr: 10.62%
[DCF] Terminal Value 76.74% ; FCFF base≈317.9m ; Y1≈364.4m ; Y5≈536.3m
[DCF] Fair Price = 27.94 (EV 7.56b - Net Debt 2.03b = Equity 5.53b / Shares 197.9m; r=8.73% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.48 | # QB: 3
Revenue Correlation: 99.73 | Revenue CAGR: 22.09% | SUE: 1.63 | # QB: 6
EPS current Quarter (2026-09-30): EPS=0.47 | Chg30d=+0.15% | Revisions=+80% | Analysts=16
EPS current Year (2026-12-31): EPS=1.82 | Chg30d=+0.05% | Revisions=+25% | GrowthEPS=+82.0% | GrowthRev=+19.0%
EPS next Year (2027-12-31): EPS=2.28 | Chg30d=+0.02% | Revisions=+82% | GrowthEPS=+25.2% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: +90% (up=27, down=0)